STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
What the filings say about ATHE
Insiders, 180 days
+$23.8K net bought
1 buyer
Alterity Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ALTERITY THERAPEUTICS LTD insiders bought a net $23.8K of stock across 1 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 24.9% of the 191,340 shares held after it.
No other insider bought within 30 days.
13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Marks Peter Ashley bought about $23.8K of ATHE on Aug 31, 2026, the largest insider purchase at the company on our record; 13 funds added in the latest 13F quarter.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
ATHE planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ATHE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$4.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
1 active
1
Not applicable
0 active
What changed recently
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
2026-10-10 · Not Yet Recruiting → Enrolling By Invitation
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $23.8K bought by insiders over 180 days, 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ATHE ranks highest on risk and compliance (89th percentile) and insider conviction (62nd), and lowest on institutional and government (23rd), among Pharma & Biotech peers.
Insider conviction
62
Inputs
Net Form 4 buying (codes P and S), 180d$24K · 68 pct, sector of 429
Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
23
Inputs
Funds adding, latest quarter13 · 23 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
89
Inputs
Short interest, % of float+0.3% · 89 pct, sector of 816
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ATHE filings, in plain words
Are Alterity Therapeutics insiders buying or selling ATHE?
In the 180 days to 2026-10-28, Alterity Therapeutics insiders were net buyers, a net $23.8K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Alterity Therapeutics insiders were net buyers of ATHE, a net $23.8K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
